MeSH term
Frequency | Condition_Probility | Adult | 48 | 0.0 |
Double-Blind Method | 11 | 0.0 |
Female | 58 | 0.0 |
Humans | 100 | 0.0 |
Male | 52 | 0.0 |
RNA, Viral/analysis | 3 | 1.0 |
Time Factors | 7 | 0.0 |
Adolescent | 18 | 0.0 |
Aged | 14 | 0.0 |
Immunohistochemistry | 3 | 0.0 |
Middle Aged | 26 | 0.0 |
Allergens/*immunology | 3 | 3.0 |
Animals | 37 | 0.0 |
Antigens, Dermatophagoides | 9 | 17.0 |
Asthma/*immunology | 11 | 12.0 |
Child | 21 | 0.0 |
Child, Preschool | 10 | 0.0 |
Comparative Study | 20 | 0.0 |
Glycoproteins/*immunology | 4 | 5.0 |
Mice | 5 | 0.0 |
Mice, SCID | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 56 | 0.0 |
Interferon Type II/biosynthesis | 2 | 0.0 |
Interleukin-4/biosynthesis | 3 | 2.0 |
Lymphocyte Activation/*drug effects | 2 | 0.0 |
Mites/*immunology | 13 | 26.0 |
Analysis of Variance | 3 | 0.0 |
*Models, Genetic | 2 | 1.0 |
Pregnancy | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 13 | 0.0 |
Antibodies, Monoclonal | 2 | 0.0 |
Antibodies, Viral/*blood | 2 | 4.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Genotype | 2 | 0.0 |
Risk Factors | 4 | 0.0 |
Case-Control Studies | 3 | 0.0 |
*Diet, Reducing | 3 | 4.0 |
Insulin/blood | 3 | 0.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Amino Acid Sequence | 5 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Kinetics | 5 | 0.0 |
Molecular Sequence Data | 9 | 0.0 |
Protein Binding | 2 | 0.0 |
Solubility | 3 | 0.0 |
Dust | 3 | 10.0 |
Antigens/*immunology | 4 | 5.0 |
Cells, Cultured | 15 | 0.0 |
Glycoproteins/immunology | 2 | 2.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
T-Lymphocytes/*metabolism | 3 | 0.0 |
Base Sequence | 7 | 0.0 |
Allergens/immunology | 2 | 2.0 |
Interleukin-1/*biosynthesis | 2 | 1.0 |
Aged, 80 and over | 2 | 0.0 |
Physical Stimulation | 2 | 4.0 |
Reference Values | 3 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Thailand | 2 | 1.0 |
English Abstract | 12 | 0.0 |
Interferon Type II/*biosynthesis | 3 | 1.0 |
Lymphocytes/*immunology/metabolism | 2 | 9.0 |
Fenfluramine/*pharmacology | 3 | 17.0 |
In Vitro | 4 | 0.0 |
Rats | 6 | 0.0 |
Transfection | 3 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Cell Division | 2 | 0.0 |
Blood Glucose/*metabolism | 2 | 0.0 |
Blood Pressure | 2 | 0.0 |
Body Mass Index | 2 | 0.0 |
Cross-Over Studies | 3 | 0.0 |
Fenfluramine/*therapeutic use | 6 | 85.0 |
Obesity/*drug therapy | 5 | 41.0 |
Placebos | 3 | 1.0 |
Weight Loss | 5 | 3.0 |
Butadienes/pharmacology | 2 | 3.0 |
Cell Line, Tumor | 2 | 0.0 |
Hamsters | 3 | 0.0 |
Nitriles/pharmacology | 2 | 1.0 |
Cardiovascular Diseases/*etiology | 2 | 6.0 |
Gene Expression | 3 | 0.0 |
Mites/immunology | 5 | 13.0 |
Immunoglobulin E/blood | 2 | 1.0 |
Fenfluramine/*pharmacology/therapeutic use | 2 | 66.0 |
Anthropometry | 2 | 0.0 |
Biological Availability | 2 | 0.0 |
Infant | 3 | 0.0 |
Filtration | 2 | 4.0 |
Immunoglobulin E/*biosynthesis | 2 | 4.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Fetus/metabolism | 2 | 1.0 |
Energy Intake | 2 | 1.0 |
Energy Metabolism/*drug effects | 2 | 11.0 |
Energy Metabolism/drug effects | 2 | 9.0 |
Oxidation-Reduction | 4 | 0.0 |
Molecular Weight | 2 | 0.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
*Energy Intake | 2 | 5.0 |
Energy Metabolism | 2 | 1.0 |
Cholesterol/blood | 2 | 0.0 |
Immunoglobulin E/biosynthesis | 2 | 5.0 |
*Dust | 2 | 14.0 |
Weight Loss/drug effects | 3 | 15.0 |
Ovalbumin/pharmacology | 2 | 25.0 |
Half-Life | 2 | 0.0 |
Isomerism | 2 | 0.0 |
Serum Albumin/*metabolism | 2 | 4.0 |
Liver/enzymology | 2 | 0.0 |
Rabbits | 2 | 0.0 |
Food Analysis | 2 | 13.0 |
Evaluation Studies | 2 | 0.0 |
Randomized Controlled Trials | 2 | 0.0 |
Mathematics | 2 | 1.0 |
Absorption | 2 | 1.0 |
Blood Glucose/analysis | 2 | 0.0 |
Dietary Fiber/*administration & dosage | 2 | 12.0 |
Leukocyte Count | 2 | 0.0 |
